71510-64-0

Basic information

• Product Name: 4-[(benzyl)amino]butyronitrile
• Synonyms: 4-[(benzyl)amino]butyronitrile;4-[(Phenylmethyl)amino]butanenitrile
• CAS NO: 71510-64-0
• Molecular Formula: C₁₁H₁₄N₂
• Molecular Weight: 174.24226
• EINECS: 275-588-7
• Mol File: 71510-64-0.mol

Chemical Properties

• Boiling Point: 318.9°C at 760 mmHg
• Flash Point: 146.6°C
• Appearance: /
• Density: 1.001g/cm³
• Vapor Pressure: 0.000352mmHg at 25°C
• Refractive Index: 1.523
• CAS DataBase Reference: 4-[(benzyl)amino]butyronitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[(benzyl)amino]butyronitrile(71510-64-0)
• EPA Substance Registry System: 4-[(benzyl)amino]butyronitrile(71510-64-0)

Safety Data

• Hazardous Substances Data: 71510-64-0(Hazardous Substances Data)

Usage

InChI:InChI=1/C11H14N2/c12-8-4-5-9-13-10-11-6-2-1-3-7-11/h1-3,6-7,13H,4-5,9-10H2

Upstream product

• 100-46-9 benzylamine 
• 5332-06-9 4-bromobutanenitrile 
• 628-20-6 4-Chlorobutyronitrile 
• 1027379-53-8 cyano acrylate 

Downstream Products

• 71510-65-1 N-(p-chloro)benzoyl-4-benzylaminobutyronitrile 
• 1400993-72-7 N-benzyl-3-cyanopropyl -1-sulfamoyl azide 
• 1400993-83-0 C₁₁H₁₅N₃O₃S 
• 1400993-70-5 C₁₁H₁₅N₅O₃S 
• 1346756-59-9 3-amino-6-benzyl-5,6-dihydro-1H-pyrazolo[3,4-c]pyridin-7(4H)-one 
• 1346756-57-7 1-benzyl-2,3-dioxopiperidine-4-carbonitrile 
• 29867-04-7 N-(4-aminobutyl)(phenylmethyl)amine 

Relevant articles and documents

Copper-Catalyzed Cyanoalkylation of Amines via C-C Bond Cleavage: An Approach for C(sp3)-N Bond Formations

The efficient copper-catalyzed cyanoalkylation of amines via C-C bond cleavage has been demonstrated. Distinctive features of this procedure involves mild conditions, broad range of nitrogen nucleophiles, high selectivity, and good functional group tolerance, thus providing a useful approach for the C(sp3)-N bond formations. Most importantly, this protocol is applicable to the late-stage functionalization of natural products, amino acid esters, and drugs. Mechanistic studies suggest that a radical intermediate was involved in this transformation.

Room temperature solvent free aza-Michael reactions over nano-cage mesoporous materials

An efficient highly acidic three dimensional mesoporous aluminosilicate nano-cage material Al-KIT5, exhibited excellent catalytic activity in solvent free room temperature aza-Michael reactions of amines with α,β- unsaturated carbonyl compounds to produce β-amino carbonyl compounds with 100% product selectivity in a short reaction time. The high acidity, 3D pores, and a huge space in the nano-cages materials make them attractive candidate for carrying out important organic reactions. The catalyst provide a simple, easy to handle method, and could be used to solve the problems of corrosion, toxicity, waste production, and a high cost that are being currently encountered by the conventional homogeneous catalysts.

Synthesis of 1,6-disubstituted 4,5,6,7-tetrahydropyrazolo[3,4-c]pyridin-7- one derivatives and evaluation of their anticancer activity

Promising anticancer compounds of the type 1,6-disubstituted 4,5,6,7-tetrahydropyrazolo[3,4-c]pyridin-7-ones were identified. The target compounds were readily synthesized in a large scale via a sequence of reactions starting from the commercially available primary amines. Their in vitro anti-proliferative activity has been evaluated on prostate (DU-145), colon (HT-29 and HCT-116) and melanoma (A375P) human cancer cell lines. The relationships between the structure and the anticancer activity, covering all tested cancer cell lines, revealed that the compound 5c with 2,4-dimethylphenyl substituent at R2 was the most potent with the IC50 values in the range as low as 0.16 to 0.40 μM.

NOVEL 1,6-DISUBSTITUTED-3-AMINO-4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[3,4-C]PYRIDIN-7-ONE COMPOUNDS AND PREPARATION THEREOF

Provided are a novel 1,6-disubstituted-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridin-7-one compound, a pharmaceutically acceptable salt compound thereof, a method for preparing the compound, and an anticancer pharmaceutical composition including the compound as an effective ingredient.

Synthesis of 2-[(arylmethylene)amino]cyclopropanecarbonitriles via a two-step ring transformation of 2-(cyanomethyl)aziridines

Reaction of 2-(cyanomethyl)aziridines with N-bromosuccinimide in dichloromethane results in the formation of 3-[(arylmethylene) amino]-4-bromobutanenitriles in high yield. The latter α-amino-γ- bromobutanenitriles were converted into separable trans- and

Central cholinergic agents. I. Potent acetylcholinesterase inhibitors, 2-[ω-[N-alkyl-N-(ω-phenylalkyl)amino]alkyl]-1H-isoindole-1,3(2H)-dion es, based on a new hypothesis of the enzyme's active site

It has been suggested that the active site of acetylcholinesterase contains a hydrophobic binding site (HBS-1), which is closely adjacent to both the anionic and the esteratic sites. In this paper, we assumed that there exists another hydrophobic binding site (HBS-2), some distance removed from the anionic site. On this assumption, a new working hypothesis was proposed for the design of acetylcholinesterase inhibitors. A series of 2-[ω-[N-alkyl-N-(ω-phenylalkyl)amino]alkyl]-1H-isoindole-1,3(2H)-dion es was designed based on this hypothesis and tested for its inhibitory activities on acetylcholinesterase. Some in this series were revealed to be more potent than physostigmine. Optimum activity was found to be associated with a five carbon chain length separating the benzylamino group from the 1H-isoindole-1,3(2H)-dione (phthalimide) moiety. Quantitative study of substitution effect on the phthalimide moiety revealed that hydrophilic and electron-withdrawing groups enhance the activity.

Acylhydrocarbylaminoalkanoic acids, compositions and uses

Compounds of the formula STR1 wherein R is (a) optionally-substituted and optionally-hydrogenated biphenylyl, (b) optionally-substituted and optionally-hydrogenated bicyclic aryl having from 8 to 12 ring carbon atoms or (c) a radical of the formula STR2 R1 is aliphatic hydrocarbyl, alicyclic hydrocarbyl or optionally-substituted phenyl; R2 is --H or lower aliphatic hydrocarbyl; R3 is --H, lower alkyl, cycloalkyl, optionally-substituted phenyl or, with R4, alkylene; R4 is lower alkyl, cycloalkyl, optionally-substituted phenyl, optionally-(nuclearly)-substituted phenalkyl or, with R3, alkylene; or R2,R3 and R4, together with the carbon to which each is bound, are adamantyl; and n is 3, 4 or 5; and salts thereof with a base are pharmacologically active. Esters thereof are valuable intermediates for the preparation of the pharmacologically-active compounds. Physiologically-acceptable embodiments are administered, e.g., in the form of an appropriate pharmaceutical composition to warm-blooded animals for protection against and treatment for stomach, intestine, pancreas, bile and liver disorders. Syntheses of pharmacologically-active components, transforming toxic embodiments to physiologically-acceptable principles, compounding such principles into pharmaceutical compositions and using such principles for preventing and treating the noted disorders are discussed.